Synonyms: CH5183284 | DEBIO-1347 | DEBIO1347
Compound class:
Synthetic organic
Comment: Zoligratinib (DEBIO1347) is a FGFR1/2/3 inhibitor that is being investigated for antineoplastic activity [1]. The compound is ATP-competitive, potent and orally available.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
DEBIO1347 is being evaluated in early phase clinical trials: Phase 1 NCT01948297 (FGFR dysregulated solid tumours; results published in 2019 [2] and progressed to extension phase), and Phase 1/2 NCT03344536 (in combination with fulvestrant for FGFR-amplified, ER+ve metastatic breast cancer). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01948297 | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations | Phase 1 Interventional | Debiopharm International SA | ||
NCT03344536 | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | Phase 1/Phase 2 Interventional | Memorial Sloan Kettering Cancer Center |